The Orienting Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
About this trial
This study at IRCCS Galeazzi - Sant'Ambrogio Hospital involves patients with gout, CPPD, and osteoarthritis as a control group. Patients will receive routine care with regular clinical, laboratory, and imaging assessments every six months, alongside urgent visits as needed. The study aims to understand crystal deposits in joints and blood vessels and monitor their progression over time, assessing how these deposits respond to standard treatments and if they are associated with cardiovascular complications. Data will be collected from medical records over a follow-up period of up to 10 years, offering long-term insights into disease impact and treatment effectiveness.
Eligibility criteria
Qualifiers
Patients diagnosed with CPPD disease according to the ACR/EULAR 2023 classification criteria.
Patients with evidence of asymptomatic CPPD on US or X-rays (not meeting the classification criteria) according to validated imaging definitions.
Aged older than 18 years.
Able to provide informed consent, according to requirements of local IRB/ethics committee.
Disqualifiers
Known history of other inflammatory arthropathies
Unable to provide informed consent, according to requirements of local IRB/ethics committee.
Known history of other inflammatory arthropathies
Unable to provide informed consent, according to requirements of local IRB/ethics committee.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
450 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov